| Peer-Reviewed

The Role of Peptide Immunotherapy in the Treatment of Cervical Dysplasia: Clinical Cases

Received: 12 April 2023     Accepted: 15 May 2023     Published: 25 May 2023
Views:       Downloads:
Abstract

Introduction. Since one of the main factors determining the pathogenic effect of HPV infection is local immunodeficiency, a number of authors suggest using various cytokines and immunomodulators. Recently, peptide-based agents have been increasingly used in routine clinical practice. Objective. To study the effect of peptide immunocorrection on molecular and cellular factors affecting the course of grade II cervical dysplasia (CIN2) as a precancerous process and to evaluate the effectiveness of the proposed regimen. Materials and methods. The study included 2 groups of patients aged 28 to 44 years who were colposcopically and cytologically diagnosed with grade 2 cervical dysplasia. Clinical monitoring, determination of HPV by PCR, immunohistochemical studies of biomarkers of inflammation and proliferation, as well as counting of T-lymphocytes in cervical mucus preparations were performed before treatment, after treatment, after 6 weeks and after 3 months. Results. During the study of the expression level of pro-oncogenic interleukin IL-8 and anti-oncogenic IL-12, it was established that in both observation groups after the immunotherapy, a tendency to decrease the pro-oncogenic potential of cervical mucus was noted. Analysis of the level of expression of the cell proliferation marker Ki-67 in the clinical monitoring groups showed that the proposed therapy schemes reduced the proliferative potential of the cervical epithelium. The number of active cytotoxic lymphocytes in the cervical mucus in both observation groups predictably increased after the use of local immunotherapy. The study showed that immunotherapy of cervical dysplasia with the use of peptides demonstrated significantly better clinical results compared to the reference group. Conclusion. Taking into account the obtained research results and the given clinical cases, peptide immunocorrection can be reasonably recommended as an immunological component in the treatment of cervical dysplasia (ASCUS and LSIL).

Published in International Journal of Clinical Oncology and Cancer Research (Volume 8, Issue 2)
DOI 10.11648/j.ijcocr.20230802.13
Page(s) 32-38
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2023. Published by Science Publishing Group

Keywords

Cervical Dysplasia, Cervical Cancer, Immunocorrection, Peptides, Effectiveness

References
[1] Al Roomy M, Chehadeh W, Al Awadhi R. Prediction of cervical cancer precursor lesions by quantitative methylation specific PCR: A retrospective study. Cytopathology. 2023 Jan 30. doi: 10.1111/cyt.13213. Epub ahead of print. PMID: 36715362.
[2] Poniewierza P, Panek G. Cervical Cancer Prophylaxis-State-of-the-Art and Perspectives. Healthcare (Basel). 2022 Jul 17; 10 (7): 1325. doi: 10.3390/healthcare10071325. PMID: 35885852; PMCID: PMC9319342.
[3] Lehtinen M, Pimenoff VN, Nedjai B, Louvanto K, Verhoef L, Heideman DAM, El-Zein M, Widschwendter M, Dillner J. Assessing the risk of cervical neoplasia in the post-HPV vaccination era. Int J Cancer. 2023 Mar 15; 152 (6): 1060-1068. doi: 10.1002/ijc.34286. Epub 2022 Oct 10. PMID: 36093582.
[4] D'Oria O, Corrado G, Laganà AS, Chiantera V, Vizza E, Giannini A. New Advances in Cervical Cancer: From Bench to Bedside. Int J Environ Res Public Health. 2022 Jun 9; 19 (12): 7094. doi: 10.3390/ijerph19127094. PMID: 35742340; PMCID: PMC9222371.
[5] Yadav C, Yadav R, Chabbra R, Nanda S, Ranga S, Kadian L, Ahuja P. Overview of genetic and epigenetic regulation of human papillomavirus and apoptosis in cervical cancer. Apoptosis. 2023 Jan 18. doi: 10.1007/s10495-023-01812-w. Epub ahead of print. Erratum in: Apoptosis. 2023 Feb 9; PMID: 36652131.
[6] Luan H. Human papilloma virus infection and its associated risk for cervical lesions: a cross-sectional study in Putuo area of Shanghai, China. BMC Womens Health. 2023 Jan 20; 23 (1): 28. doi: 10.1186/s12905-023-02166-w. PMID: 36658539; PMCID: PMC9854058.
[7] Qin D, Bai A, Xue P, Seery S, Wang J, Mendez MJG, Li Q, Jiang Y, Qiao Y. Colposcopic accuracy in diagnosing squamous intraepithelial lesions: a systematic review and meta-analysis of the International Federation of Cervical Pathology and Colposcopy 2011 terminology. BMC Cancer. 2023 Feb 23; 23 (1): 187. doi: 10.1186/s12885-023-10648-1. PMID: 36823557; PMCID: PMC9951444.
[8] Becker S, Jonigk D, Luft A, Dübbel L, Werlein C, Malik E, Schild-Suhren M. COVID-19 can lead to rapid progression of cervical intraepithelial neoplasia by dysregulating the immune system: A hypothesis. J Reprod Immunol. 2022 Dec; 154: 103763. doi: 10.1016/j.jri.2022.103763. Epub 2022 Nov 9. PMID: 36399874; PMCID: PMC9645588.
[9] Sarma U, Das GC, Sarmah B. Predictive Value of Marker of Proliferation Ki-67 and Cell Cycle Dependent Protein kinase Inhibitor P16INK4a in Cervical Biopsy to Determine Its Biological Behaviour. Asian Pac J Cancer Prev. 2021 Jul 1; 22 (7): 2237-2241. doi: 10.31557/APJCP.2021.22.7.2237. PMID: 34319047; PMCID: PMC8607082.
[10] Vahedpour Z, Abedzadeh-Kalahroudi M, Sehat M, Piroozmand A, Memar M. Comparison of Cervical Levels of Interleukins-6 and -8 in Patients with and without Cervical Intraepithelial Neoplasia. Asian Pac J Cancer Prev. 2021 Apr 1; 22 (4): 1225-1230. doi: 10.31557/APJCP.2021.22.4.1225. PMID: 33906316; PMCID: PMC8325114.
[11] Osiagwu DD, Azenabor AE, Osijirin AA, Awopetu PI, Oyegbami FR. Evaluation of interleukin 8 and interleukin 10 cytokines in liquid based cervical cytology samples. Pan Afr Med J. 2019 Mar 26; 32: 148. doi: 10.11604/pamj.2019.32.148.16314. PMID: 31303919; PMCID: PMC6607241.
[12] Bonin-Jacob CM, Almeida-Lugo LZ, Puga MAM, Machado AP, Padovani CTJ, Noceti MC, et al. (2021) IL-6 and IL-10 in the serum and exfoliated cervical cells of patients infected with high-risk human papillomavirus. PLoS ONE 16 (3): e0248639. https://doi.org/10.1371/journal.pone.0248639
[13] Litwin TR, Irvin SR, Chornock RL, Sahasrabuddhe VV, Stanley M, Wentzensen N. Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. Br J Cancer. 2021 Feb; 124 (4): 831-841. doi: 10.1038/s41416-020-01184-x. Epub 2020 Dec 1. PMID: 33257839; PMCID: PMC7884592.
[14] Carrero YN, Callejas DE, Mosquera JA. In situ immunopathological events in human cervical intraepithelial neoplasia and cervical cancer: Review. Transl Oncol. 2021 May; 14 (5): 101058. doi: 10.1016/j.tranon.2021.101058. Epub 2021 Mar 4. PMID: 33677234; PMCID: PMC7937982.
[15] Zhang L, Mao Z, Lai Y, Wan T, Zhang K, Zhou B. A review of the research progress in T-lymphocyte immunity and cervical cancer. Transl Cancer Res. 2020 Mar; 9 (3): 2026-2036. doi: 10.21037/tcr.2020.01.33. PMID: 35117549; PMCID: PMC8797462.
[16] Desravines N, Miele K, Carlson R, Chibwesha C, Rahangdale L. Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2-3: A narrative review. Gynecol Oncol Rep. 2020 Jul 2; 33: 100608. doi: 10.1016/j.gore.2020.100608. PMID: 32685652; PMCID: PMC7356206.
[17] Muntinga CLP, de Vos van Steenwijk PJ, Bekkers RLM, van Esch EMG. Importance of the Immune Microenvironment in the Spontaneous Regression of Cervical Squamous Intraepithelial Lesions (cSIL) and Implications for Immunotherapy. J Clin Med. 2022 Mar 5; 11 (5): 1432. doi: 10.3390/jcm11051432. PMID: 35268523; PMCID: PMC8910829.
[18] Moretta A, Scieuzo C, Petrone AM, Salvia R, Manniello MD, Franco A, Lucchetti D, Vassallo A, Vogel H, Sgambato A, Falabella P. Antimicrobial Peptides: A New Hope in Biomedical and Pharmaceutical Fields. Front Cell Infect Microbiol. 2021 Jun 14; 11: 668632. doi: 10.3389/fcimb.2021.668632. PMID: 34195099; PMCID: PMC8238046.
[19] Haidari H, Melguizo-Rodríguez L, Cowin AJ, Kopecki Z. Therapeutic potential of antimicrobial peptides for treatment of wound infection. Am J Physiol Cell Physiol. 2023 Jan 1; 324 (1): C29-C38. doi: 10.1152/ajpcell.00080.2022. Epub 2022 Nov 21. PMID: 36409176.
[20] Mulkern AJ, Oyama LB, Cookson AR, Creevey CJ, Wilkinson TJ, Olleik H, Maresca M, da Silva GC, Fontes PP, Bazzolli DMS, Mantovani HC, Damaris BF, Mur LAJ, Huws SA. Microbiome-derived antimicrobial peptides offer therapeutic solutions for the treatment of Pseudomonas aeruginosa infections. NPJ Biofilms Microbiomes. 2022 Aug 29; 8 (1): 70. doi: 10.1038/s41522-022-00332-w. PMID: 36038584; PMCID: PMC9424236.
[21] Jafari A, Babajani A, Sarrami Forooshani R, Yazdani M, Rezaei-Tavirani M. Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside. Front Oncol. 2022 Feb 23; 12: 819563. doi: 10.3389/fonc.2022.819563. PMID: 35280755; PMCID: PMC8904739.
[22] Kordi M, Borzouyi Z, Chitsaz S, Asmaei MH, Salami R, Tabarzad M. Antimicrobial peptides with anticancer activity: Today status, trends and their computational design. Arch Biochem Biophys. 2023 Jan 1; 733: 109484. doi: 10.1016/j.abb.2022.109484. Epub 2022 Dec 5. PMID: 36473507.
[23] Kurchenko A et al., Anti-recurrent Immunocorrection in Gynecology Andrology and Proctology. Int J of Immunology. 2020. Vol. 8 (1): 1-8.
[24] Zakharenko N et al. Prospects for the Treatment of Endometriosis: The Effect of Immune Peptides on the Reactivation of Immune Surveillance over Ectopic Endometrial Cells. Journal of Gynecology and Obstetrics. Vol. 8, No. 5, 2020, 148-153.
[25] Stoler MH, Wright TC Jr, Parvu V, Yanson K, Cooper CK, Andrews JA. Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial. Gynecol Oncol. 2023 Mar; 170: 143-152. doi: 10.1016/j.ygyno.2023.01.004. Epub 2023 Jan 22. PMID: 36682092.
[26] Choi S, Ismail A, Pappas-Gogos G, Boussios S. HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK. Pathogens. 2023 Feb 11; 12 (2): 298. doi: 10.3390/pathogens12020298. PMID: 36839570; PMCID: PMC9960303.
[27] Hughes KC, Herring TA, Song JN, Gately RV, Przybyl LM, Ogilvie RP, Simon K, Bhuyan PK, Kyrgiou M, Seeger JD. Cervical High-Grade Squamous Intraepithelial Lesion Burden and Standard of Care Treatment Effectiveness and Safety in the United States, 2008-2018: The EACH-WOMAN Project. J Low Genit Tract Dis. 2023 Apr 1; 27 (2): 105-112. doi: 10.1097/LGT.0000000000000719. Epub 2023 Feb 23. PMID: 36815642.
[28] Viveros-Carreño D, Fernandes A, Pareja R. Updates on cervical cancer prevention. Int J Gynecol Cancer. 2023 Mar 6; 33 (3): 394-402. doi: 10.1136/ijgc-2022-003703. PMID: 36878567.
[29] Kaur S, Sharma LM, Mishra V, Goyal MGB, Swasti S, Talele A, Parikh PM. Challenges in Cervical Cancer Prevention: Real-World Scenario in India. South Asian J Cancer. 2023 Feb 25; 12 (1): 9-16. doi: 10.1055/s-0043-1764222. PMID: 36851931; PMCID: PMC9966165.
[30] Jiang G, Wu Q, Li B. Evaluation of immunotherapy efficacy in gynecologic cancer. Front Immunol. 2023 Jan 31; 14: 1061761. doi: 10.3389/fimmu.2023.1061761. PMID: 36793735; PMCID: PMC9922993.
[31] Tang M, Cai JH, Diao HY, Guo WM, Yang X, Xing S. The progress of peptide vaccine clinical trials in gynecologic oncology. Hum Vaccin Immunother. 2022 Nov 30; 18 (5): 2062982. doi: 10.1080/21645515.2022.2062982. Epub 2022 Jun 10. PMID: 35687860; PMCID: PMC9450897.
[32] Liu X, Peng J, He J, Li Q, Zhou J, Liang X, Tang S. Selection and identification of novel peptides specifically targeting human cervical cancer. Amino Acids. 2018 May; 50 (5): 577-592. doi: 10.1007/s00726-018-2539-1. Epub 2018 Feb 12. PMID: 29435721.
[33] Ahmed S, Khan H, Fakhri S, Aschner M, Cheang WS. Therapeutic potential of marine peptides in cervical and ovarian cancers. Mol Cell Biochem. 2022 Feb; 477 (2): 605-619. doi: 10.1007/s11010-021-04306-y. Epub 2021 Dec 2. PMID: 34855045.
Cite This Article
  • APA Style

    Оlga Bulavenko, Тetiana Lunko, Оleksii Таtskyy, Тetiana Fomina, Мaria Pikul, et al. (2023). The Role of Peptide Immunotherapy in the Treatment of Cervical Dysplasia: Clinical Cases. International Journal of Clinical Oncology and Cancer Research, 8(2), 32-38. https://doi.org/10.11648/j.ijcocr.20230802.13

    Copy | Download

    ACS Style

    Оlga Bulavenko; Тetiana Lunko; Оleksii Таtskyy; Тetiana Fomina; Мaria Pikul, et al. The Role of Peptide Immunotherapy in the Treatment of Cervical Dysplasia: Clinical Cases. Int. J. Clin. Oncol. Cancer Res. 2023, 8(2), 32-38. doi: 10.11648/j.ijcocr.20230802.13

    Copy | Download

    AMA Style

    Оlga Bulavenko, Тetiana Lunko, Оleksii Таtskyy, Тetiana Fomina, Мaria Pikul, et al. The Role of Peptide Immunotherapy in the Treatment of Cervical Dysplasia: Clinical Cases. Int J Clin Oncol Cancer Res. 2023;8(2):32-38. doi: 10.11648/j.ijcocr.20230802.13

    Copy | Download

  • @article{10.11648/j.ijcocr.20230802.13,
      author = {Оlga Bulavenko and Тetiana Lunko and Оleksii Таtskyy and Тetiana Fomina and Мaria Pikul and Оleksandr Zdanevych and Mykhailo Каzarnovskyy and Victor Zadorozhnyy and Svitlana Тurbanist and Svitlana Pysmenna and Olena Yamkova-Bodnaruk and Liudmyla Lytvynchuk},
      title = {The Role of Peptide Immunotherapy in the Treatment of Cervical Dysplasia: Clinical Cases},
      journal = {International Journal of Clinical Oncology and Cancer Research},
      volume = {8},
      number = {2},
      pages = {32-38},
      doi = {10.11648/j.ijcocr.20230802.13},
      url = {https://doi.org/10.11648/j.ijcocr.20230802.13},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcocr.20230802.13},
      abstract = {Introduction. Since one of the main factors determining the pathogenic effect of HPV infection is local immunodeficiency, a number of authors suggest using various cytokines and immunomodulators. Recently, peptide-based agents have been increasingly used in routine clinical practice. Objective. To study the effect of peptide immunocorrection on molecular and cellular factors affecting the course of grade II cervical dysplasia (CIN2) as a precancerous process and to evaluate the effectiveness of the proposed regimen. Materials and methods. The study included 2 groups of patients aged 28 to 44 years who were colposcopically and cytologically diagnosed with grade 2 cervical dysplasia. Clinical monitoring, determination of HPV by PCR, immunohistochemical studies of biomarkers of inflammation and proliferation, as well as counting of T-lymphocytes in cervical mucus preparations were performed before treatment, after treatment, after 6 weeks and after 3 months. Results. During the study of the expression level of pro-oncogenic interleukin IL-8 and anti-oncogenic IL-12, it was established that in both observation groups after the immunotherapy, a tendency to decrease the pro-oncogenic potential of cervical mucus was noted. Analysis of the level of expression of the cell proliferation marker Ki-67 in the clinical monitoring groups showed that the proposed therapy schemes reduced the proliferative potential of the cervical epithelium. The number of active cytotoxic lymphocytes in the cervical mucus in both observation groups predictably increased after the use of local immunotherapy. The study showed that immunotherapy of cervical dysplasia with the use of peptides demonstrated significantly better clinical results compared to the reference group. Conclusion. Taking into account the obtained research results and the given clinical cases, peptide immunocorrection can be reasonably recommended as an immunological component in the treatment of cervical dysplasia (ASCUS and LSIL).},
     year = {2023}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - The Role of Peptide Immunotherapy in the Treatment of Cervical Dysplasia: Clinical Cases
    AU  - Оlga Bulavenko
    AU  - Тetiana Lunko
    AU  - Оleksii Таtskyy
    AU  - Тetiana Fomina
    AU  - Мaria Pikul
    AU  - Оleksandr Zdanevych
    AU  - Mykhailo Каzarnovskyy
    AU  - Victor Zadorozhnyy
    AU  - Svitlana Тurbanist
    AU  - Svitlana Pysmenna
    AU  - Olena Yamkova-Bodnaruk
    AU  - Liudmyla Lytvynchuk
    Y1  - 2023/05/25
    PY  - 2023
    N1  - https://doi.org/10.11648/j.ijcocr.20230802.13
    DO  - 10.11648/j.ijcocr.20230802.13
    T2  - International Journal of Clinical Oncology and Cancer Research
    JF  - International Journal of Clinical Oncology and Cancer Research
    JO  - International Journal of Clinical Oncology and Cancer Research
    SP  - 32
    EP  - 38
    PB  - Science Publishing Group
    SN  - 2578-9511
    UR  - https://doi.org/10.11648/j.ijcocr.20230802.13
    AB  - Introduction. Since one of the main factors determining the pathogenic effect of HPV infection is local immunodeficiency, a number of authors suggest using various cytokines and immunomodulators. Recently, peptide-based agents have been increasingly used in routine clinical practice. Objective. To study the effect of peptide immunocorrection on molecular and cellular factors affecting the course of grade II cervical dysplasia (CIN2) as a precancerous process and to evaluate the effectiveness of the proposed regimen. Materials and methods. The study included 2 groups of patients aged 28 to 44 years who were colposcopically and cytologically diagnosed with grade 2 cervical dysplasia. Clinical monitoring, determination of HPV by PCR, immunohistochemical studies of biomarkers of inflammation and proliferation, as well as counting of T-lymphocytes in cervical mucus preparations were performed before treatment, after treatment, after 6 weeks and after 3 months. Results. During the study of the expression level of pro-oncogenic interleukin IL-8 and anti-oncogenic IL-12, it was established that in both observation groups after the immunotherapy, a tendency to decrease the pro-oncogenic potential of cervical mucus was noted. Analysis of the level of expression of the cell proliferation marker Ki-67 in the clinical monitoring groups showed that the proposed therapy schemes reduced the proliferative potential of the cervical epithelium. The number of active cytotoxic lymphocytes in the cervical mucus in both observation groups predictably increased after the use of local immunotherapy. The study showed that immunotherapy of cervical dysplasia with the use of peptides demonstrated significantly better clinical results compared to the reference group. Conclusion. Taking into account the obtained research results and the given clinical cases, peptide immunocorrection can be reasonably recommended as an immunological component in the treatment of cervical dysplasia (ASCUS and LSIL).
    VL  - 8
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Obstetrics and Gynecology, No. 2 of M. I. Pyrogov Vinnytskyy National Medical University, Vinnytsia, Ukraine

  • Department of Obstetrics and Gynecology, Odeskyy National Medical University, Odesa, Ukraine

  • Department of Research and Development, International Biotherapy Institute, Kyiv, Ukraine

  • Department of Gynecology, Women's Health Center "Remedivin", Vinnytsia, Ukraine

  • Department of Gynecology, Cherkasy Regional Clinical Hospital, Cherkasy, Ukraine

  • Department of Oncogynecology, Cherkasy Regional Oncology Dispensary, Cherkasy, Ukraine

  • Department of Oncogynecology, Odesa Regional Clinical Antitumor Center, Odesa, Ukraine

  • Department of Oncogynecology, Odesa Regional Clinical Antitumor Center, Odesa, Ukraine

  • Department of Gynecology, Private Gynecological Clinic "Isida", Kyiv, Ukraine

  • Department of Gynecology, Women's Consultation No. 2, Cherkasy, Ukraine

  • Department of Gynecology, Medical Center "Innomed ", Vinnytsia, Ukraine

  • Department of Oncogynecology, Podilskyy Regional Oncology Center, Vinnytsia, Ukraine

  • Sections